VS-6063

defactinib · Verastem, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for VS-6063, covering 2017-01-30 to 2017-05-17. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer [Phase 1]